Your search for oral corticosteroids returned 12 results

Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.

The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.

Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.

Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.

A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.

A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.

To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?

NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.

A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.

The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.